<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007743</url>
  </required_header>
  <id_info>
    <org_study_id>27/7/18</org_study_id>
    <nct_id>NCT05007743</nct_id>
  </id_info>
  <brief_title>Effects of Transcutaneous Vagus Nerve Stimulation in Chronic Pain Patients and Healthy Controls</brief_title>
  <acronym>tVNS-PP</acronym>
  <official_title>Randomized Trial of Effects of Transcutaneous Vagus Nerve Stimulation in Chronic Pain Patients and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tVNS-PP trial investigates the effects of transcutaneous vagus nerve stimulation (tVNS)&#xD;
      on autonomic functions, immune responses, and disease severity in chronic pain and restless&#xD;
      legs syndrome (RLS) patients as compared to healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot study with healthy participants will investigate whether transcutaneous vagus nerve&#xD;
      stimulation at the inner tragus reduces heart rate variability and lowers blood pressure&#xD;
      without causing undesirable, severe side effects. In addition, changes in immune markers will&#xD;
      be analyzed in blood samples before and after the interventions. Patients with primary&#xD;
      restless legs syndrome will undergo a similar experimental protocol, except that&#xD;
      transcutaneous vagus nerve stimulation will be performed daily. The aim is to determine&#xD;
      whether stimulation reduces disease severity and chronic pain while improving quality of&#xD;
      life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A crossover design is used for the investigation of the healthy cohort and a parallel design will be used for the patient group</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International RLS Severity Scale</measure>
    <time_frame>Seven days</time_frame>
    <description>Numeric score quantifying disease severity. This numeric rating scale ranges from 0 to 40 points.&#xD;
The higher the achieved score, the higher is the RLS disease severity. 0 points: no symptoms, 1-10 points: mild symptoms, 11-20 points: moderate symptoms, 21-30 points: severe symptoms, 31-40 points: extreme symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time domain analysis of heart rate variability</measure>
    <time_frame>Two days</time_frame>
    <description>The standard deviation of the RR intervals (SDNN) and the root mean square of successive differences (RMSSD) in milliseconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spectral analysis of heart rate variability</measure>
    <time_frame>Two days</time_frame>
    <description>The normalized high frequency component of the RR intervals (HF-HRV) is expressed as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous baroreceptor sensitivity</measure>
    <time_frame>Two days</time_frame>
    <description>The average baroreceptor sensitivity in ms/mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine concentrations</measure>
    <time_frame>Two days</time_frame>
    <description>Interleukin-6, interleukin-8, interleukin-1ß and tumor necrosis factor alpha in pg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression scale</measure>
    <time_frame>Two days</time_frame>
    <description>This questionnaire has 14 items that evaluate depression and anxiety symptoms. Each item has four possible responses and is scored in a range from zero to three with higher scores representing more symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median nerve stimulation</measure>
    <time_frame>Two days</time_frame>
    <description>Electrical nerve stimulation of the median nerve to assess its strength-duration time constant (SDTC) or chronaxie in milliseconds. The SDTC is a measure of axonal excitability and provides indirect information about the functionality of sodium ion channels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudoscan</measure>
    <time_frame>Two days</time_frame>
    <description>Measurement of electrochemical skin conductance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Two days</time_frame>
    <description>This questionnaire assesses pain severity, location of pain, and impact on daily functions in the past 24 hours. Pain severity is scored on a numeric scale from zero to ten, with zero being no pain and ten being the worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 12 (SF-12)</measure>
    <time_frame>Two days</time_frame>
    <description>This questionnaire assesses the quality of life using 12 items. Each item is scaled on a range between zero and a maximum of six. Weighted sums are calculated and transformed into a population-standardized score ranging between zero and 100. The higher the score, the better is the respective life quality compared to the average population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Stimulation of inner tragus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stimulation of ear lobe</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous vagus nerve stimulation</intervention_name>
    <description>Frequency of 30 Hz, biphasic, rectangular pulses with a pulse width of 250 µs and an intensity of 20 mA.&#xD;
Device: Easy Tens+ device (body clock, London, UK)</description>
    <arm_group_label>Stimulation of ear lobe</arm_group_label>
    <arm_group_label>Stimulation of inner tragus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male and female participants between 18 and 80 years old&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Age younger than 18 years or older than 80 years&#xD;
&#xD;
          -  Participants with somatic or mental comorbidities, especially malignant tumor&#xD;
             diseases, cardiac insufficiencies &gt; NYHA II, severe depressive episodes, psychosis or&#xD;
             dementia&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Addictions to alcohol, medications or drugs (except tobacco)&#xD;
&#xD;
          -  An existing legal guardianship&#xD;
&#xD;
          -  Participation in another scientific study within the previous eight weeks before&#xD;
             enrollment&#xD;
&#xD;
          -  Restless Legs Syndrome patients with one of the following secondary predispositions:&#xD;
             iron deficiency, polyneuropathy, prolapsed disk, spinal stenosis or chronic&#xD;
             obstructive pulmonary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Meyer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Göttingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Veiz, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Göttingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Herrmann-Lingen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Göttingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Meyer, Prof.</last_name>
    <phone>+495513964940</phone>
    <email>thomas.meyer@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk Czesnik, PD Dr.</last_name>
    <email>dczesni@gwdg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Meyer, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Goettingen</investigator_affiliation>
    <investigator_full_name>Prof. Thomas Meyer</investigator_full_name>
    <investigator_title>Head of Laboratory</investigator_title>
  </responsible_party>
  <keyword>RLS, vagus nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

